<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347902</url>
  </required_header>
  <id_info>
    <org_study_id>Lipids-5 year</org_study_id>
    <nct_id>NCT04347902</nct_id>
  </id_info>
  <brief_title>Lipid Emulsions and Liver Function - Results After 5 Years.</brief_title>
  <acronym>5ylipids</acronym>
  <official_title>Intravenous Lipid Emulsions and Liver Function in Adult Chronic Intestinal Failure Patients: New Results After 5 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanley Dudrick's Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanley Dudrick's Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous lipid emulsion (ILE) is an essential component of parenteral nutrition (PN), but
      also one of the key risk factors for development of intestinal failure associated liver
      disease (IFALD). The aim of the study was to analyse the influence of ILEs on liver function
      during long term PN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous lipid emulsion (ILE) is an essential component of parenteral nutrition (PN), but
      also one of the key risk factors for development of intestinal failure associated liver
      disease (IFALD). Despite of many commercially available ILEs with hypothetically different
      impact on liver, a direct comparison of them has never been performed. Therefore the aim of
      the study was to analyse the influence of ILEs on liver function during long term PN. Ths
      study is a continuation of the previous trial, NCT03044639.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver disfunction</measure>
    <time_frame>5 years</time_frame>
    <description>Liver tests results during parenteral nutrition</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Liver Failure</condition>
  <condition>Parenteral Nutrition-Related Hepatitis</condition>
  <arm_group>
    <arm_group_label>PN with SMOFLipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parenteral nutrition with MCT/LCT/olive oil/fish oil (SMOFLipid, Fresenius Kabi, Germany, SMOF group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PN with Olive oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parenteral nutrition with Olive oil/LCT 80:20 (ClinOleic, Baxter Healthcare, USA, OO group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PN with MCT/LCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parenteral nutrition with - Medium/long-chain triglycerides 50:50 (Lipofundin, B Braun Germany, MCT/LCT group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Lipid Emulsion</intervention_name>
    <description>Various types of intravenous lipids</description>
    <arm_group_label>PN with MCT/LCT</arm_group_label>
    <arm_group_label>PN with Olive oil</arm_group_label>
    <arm_group_label>PN with SMOFLipid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years of age,

          -  chronic intestinal failure on PN including lipids,

          -  metabolic stability (the absence of pathological laboratory resulting in the change of
             PN regime for at least one month)

          -  ability to tolerate up to 1.0 g lipids/kg body weight per day as a part of PN

        Exclusion Criteria:

          -  preexisting liver dysfunction (an elevation of SGOT, SGTP, total bilirubin, GGTP,
             alkaline phosphatase of more than 3 times x normal value),

          -  patients with a history of cancer and anti-cancer treatment within the last 5 years,

          -  severe hyperlipidemia,

          -  severe coagulopathy,

          -  severe renal insufficiency,

          -  acute thromboembolic events,

          -  positive test for HIV, Hepatitis B or C (from medical history),

          -  known or suspected drug or alcohol abuse,

          -  participation in another interventional clinical trial in parallel or within three
             months prior to the start of this clinical trial,

          -  for women with childbearing potential (i.e. females who are not chemically or
             surgically sterile or females who are not postmenopausal) or women of childbearing
             potential tested positive on standard pregnancy test (urine dipstick) or/and
             lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanislaw Klek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanley Dudrick's Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanley Dudrick's Memorial Hospital</name>
      <address>
        <city>Skawina</city>
        <zip>32-050</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Klek S, Szczepanek K, Scislo L, Walewska E, Pietka M, Pisarska M, Pedziwiatr M. Intravenous lipid emulsions and liver function in adult chronic intestinal failure patients: results from a randomized clinical trial. Nutrition. 2018 Nov;55-56:45-50. doi: 10.1016/j.nut.2018.03.008. Epub 2018 Mar 22.</citation>
    <PMID>29960156</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanley Dudrick's Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Stanislaw Klek</investigator_full_name>
    <investigator_title>Head of the General Surgery Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fat Emulsions, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

